---
document_datetime: 2025-09-30 15:24:44
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/sitagliptin-metformin-hydrochloride-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: sitagliptin-metformin-hydrochloride-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 6.8408027
conversion_datetime: 2025-12-30 21:03:52.016228
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

## Sitagliptin Metformin hydrochloride Mylan

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneed toalsorefertoEPAR-Procedural steps takenand scientific information after authorisation (archive).

| Applicationnumber   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued² / amended on   | Product Information affected3   | Summary   |
|---------------------|----------------------------------------|-------------------------------------|--------------------------------------------|---------------------------------|-----------|
| Article 61(3) /     | -Notificationacc.Article61(3)-Accepted | 30/09/2025                          |                                            | Labelling and                   |           |

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/N/0000302331                      | Update of the labelling (annex IIIA) to align the grey-shaded text in this annex with the currentapprovedmock-up/specimenlayout andupdateofthepackageleafletwith revised contact details of local representatives. Additionally, a minor typo mistakeshavebeencorrectedinthe Slovakia and GermanyProductInformation.                                                                                                                                                                                                                                                                                     |            |     | PL   |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|
| Variation type IB / EMA/VR/0000272083 | This was an applicationfor a group of variationsfollowing aworksharingprocedure accordingtoArticle20ofCommission Regulation(EC)No 1234/2008. B.II.e.2 Change in the specification parameters and/or limits of the immediate packaging of the finished product-B.II.e.2.z Otherchanges-Accepted B.II.e.2 Change in the specification parameters and/or limits of the immediate packaging of the finished product - B.II.e.2.z Other changes-Accepted B.II.e.2 Change in the specification parameters and/or limits of the immediate packaging of the finished product - B.II.e.2.z Other changes-Accepted | 17/07/2025 | N/A |      |

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000268655    | This was an applicationfor a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.e)Container closure system-B.II.e.z Othervariation-Accepted                                                                                                                                                                                                                                                                                    | 10/07/2025   | N/A   |                       |
|------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------------|
| Variation type IA / EMA/VR/0000269412    | A. ADMINISTRATIVE CHANGES - A.4 Change in thename and/oraddress of:a manufacturer(including whererelevant quality control testing sites);or an ASMF holder;or a supplier of the active substance, startingmaterial,reagentorintermediate usedinthemanufactureof theactive substance(where specified in the technical dossier)where noPh.Eur.Certificate of Suitability ispartof the approved dossier;or a manufacturer of a novel excipient (where specified in the technical dossier)- Accepted | 29/05/2025   | N/A   |                       |
| Variation type IA_IN / EMA/VR/0000261750 | C.1.3 Change(s) in the Summary of Product Characteristics,Labelling orPackageLeaflet ofhuman medicinal products intended to implementtheoutcomeofaprocedure concerningPSURorPASS,or the outcome of theassessmentdonebythecompetent                                                                                                                                                                                                                                                               | 03/04/2025   |       | SmPC, Annex II and PL |

<div style=\"page-break-after: always\"></div>

| authorityunderArticles45or46of Regulation 1901/2006 - C.1.3.a Implementation of wording agreed by the competent authority-Accepted A.ADMINISTRATIVECHANGES-A.7 Deletion ofmanufacturingsitesfor an active substance,intermediate orfinished product, packaging site,manufacturerresponsiblefor batchrelease，sitewherebatchcontroltakes place, or supplier of a starting material, reagent orexcipient(when mentioned in the dossier)*-Accepted   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|